International Journal of Clinical Oncology最新文献

{"title":"Clinical indications and implications of metastasis-directed therapy and primary-site treatment in metastatic urothelial carcinoma.","authors":"Ryoichi Saito, Takeshi Sano, Toru Kanno, Rihito Aizawa, Akihiro Hamada, Toru Sakatani, Yuki Kita, Kimihiko Masui, Takashi Ogata, Takayuki Goto, Atsuro Sawada, Takashi Mizowaki, Takashi Kobayashi","doi":"10.1007/s10147-026-03171-3","DOIUrl":"10.1007/s10147-026-03171-3","url":null,"abstract":"<p><p>Metastatic urothelial carcinoma (mUC) is traditionally managed with systemic therapy; however, long-term disease control remains uncommon despite advances such as immune checkpoint inhibitors and antibody-drug conjugates. Interest has grown in integrating metastasis-directed therapy (MDT), including metastasectomy and stereotactic body radiotherapy (SBRT), and primary-site treatment (PST) in selected patients, aiming to reduce tumor burden, eliminate resistant clones, and enhance systemic therapy outcomes. Metastasectomy is not standard but may be considered for oligometastatic patients with good performance status and a favorable response to first-line therapy. Retrospective series have shown feasibility and durable control, especially with solitary lung or nodal metastases, although data are limited by selection bias and a lack of randomized trials. SBRT offers high local control and palliation, with a growing role in oligometastatic or oligoprogressive disease to delay progression and complement immunotherapy. PST after a favorable systemic response for metastatic bladder cancer, including conversion or consolidative cystectomy and palliative or ablative radiotherapy, provides additional disease control and symptom relief. In metastatic upper tract urothelial carcinoma, retrospective and SEER-based data studies similarly suggest a survival benefit from nephroureterectomy in selected patients. Circulating tumor DNA is emerging as a complementary biomarker for patient selection and response monitoring in advanced UC cases. Most evidence predates highly effective systemic therapies; thus, the clinical value and optimal integration of MDT and PST remain to be defined, requiring prospective validation and refined patient selection.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2114-2125"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148764793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Facility-level JSMO specialist availability and reconstructable treatment-process measures in colorectal cancer using C-CAT data.","authors":"Shinya Kajiura, Hironaga Satake, Naohiko Nakamura, Ryuji Hayashi","doi":"10.1007/s10147-026-03136-6","DOIUrl":"10.1007/s10147-026-03136-6","url":null,"abstract":"<p><strong>Background: </strong>C-CAT lacks patient-level data on Japanese Society of Medical Oncology (JSMO) specialist involvement. We assessed facility-level registry-listed JSMO specialist availability and C-CAT-reconstructable treatment-process and endpoint-ascertainment measures in colorectal cancer.</p><p><strong>Methods: </strong>This nationwide retrospective C-CAT facility-level analysis included 11,906 patients at 261 facilities. The primary exposure was facility-level JSMO specialist count (0-3 vs 4 +); the secondary exposure was gastrointestinal-domain JSMO specialist presence. The primary endpoint was time from systemic therapy start to recorded second-line treatment end. Facility-cluster robust Cox models were used. Endpoint ascertainment, missingness-focused sensitivity analyses, and overall survival (OS) were supportive/contextual.</p><p><strong>Results: </strong>Overall, 5349 patients at 181 facilities were in the 0-3 group and 6557 patients at 80 facilities in the 4 + group. Median time to recorded second-line treatment end was 20.2 versus 23.1 months (log-rank p < 0.001). In facility-cluster robust Cox models, the unadjusted HR for 4 + versus 0-3 specialists was 0.840 (95% CI 0.761-0.927; p < 0.001), attenuating after facility-category adjustment (HR, 0.948; 95% CI 0.853-1.055; p = 0.329) and clinical adjustment (HR, 0.968; 95% CI 0.866-1.082; p = 0.565). Second-line end-date availability was lower in the 4 + group (61.6% vs 69.1%). Supportive OS showed no specialist-associated survival advantage (median, 50.2 vs 51.3 months; clinically adjusted HR, 0.962; 95% CI 0.816-1.135; p = 0.648).</p><p><strong>Conclusions: </strong>C-CAT can reconstruct facility-level treatment-process and endpoint-ascertainment measures, but current C-CAT data do not support specialist-attributable clinical interpretation. Direct evaluation requires chemotherapy-specific national database elements.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2282-2292"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pain response to re-irradiation for non-bone metastatic lesions: a single-institution retrospective study.","authors":"Kenji Makita, Yuichi Hiroshima, Masaki Nakamura, Hidenari Hirata, Masashi Wakabayashi, Satoshi Saito, Sadamoto Zenda","doi":"10.1007/s10147-026-03151-7","DOIUrl":"10.1007/s10147-026-03151-7","url":null,"abstract":"<p><strong>Background: </strong>Evidence regarding palliative re-irradiation (re-RT) for persistent or recurrent pain from non-bone metastatic lesions remains limited. This study evaluated pain response after re-RT in patients with persistent or recurrent painful non-bone metastases.</p><p><strong>Methods: </strong>We retrospectively analyzed patients with persistent or recurrent painful non-bone metastases who underwent re-RT to the same previously irradiated lesion between January 2013 and October 2025 and had an evaluable pain assessment at 4 weeks, defined as 28 ± 7 days after re-RT initiation. Pain response was evaluated based on changes in pain scores and morphine dosage. Assessments were performed at 7 ± 3, 28 ± 7, 56 ± 7, and 84 ± 7 days after the initiation of re-RT, corresponding to approximately 1, 4, 8, and 12 weeks, respectively.</p><p><strong>Results: </strong>Thirty-nine patients were included. The median follow-up was 128 days (interquartile range, 89-221 days). Re-RT regimens were 8 Gy in one fraction in 26 patients (67%), 20 Gy in five fractions in 12 (31%), and 30 Gy in 10 fractions in one (3%). The best overall pain response was observed in 26 patients (67%), including complete response in seven (18%) and partial response in 19 (49%). Among responders, 89% (23/26) achieved response within 4 weeks. The overall response rates were 25% (9/36) at 1 week, 51% (20/39) at 4 weeks, 63% (19/30) at 8 weeks, and 40% (10/25) at 12 weeks, respectively.</p><p><strong>Conclusion: </strong>In this small retrospective cohort, approximately half of the patients achieved pain relief after palliative re-RT, and most observed responses occurred within 4 weeks. These preliminary findings warrant further evaluation in larger prospective studies using standardized pain and analgesic assessments.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2435-2440"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148548940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of a new surgical indicator for lung cancer with interstitial lung disease based on the gender-age-physiology staging system.","authors":"Yoshito Imamura, Keita Nakanishi, Heng Huang, Minoru Sugihara, Taiki Ryo, Yasuhisa Ichikawa, Tatsuya Masuda, Hirofumi Takenaka, Yuta Kawasumi, Hiroki Watanabe, Yuka Kadomatsu, Harushi Ueno, Taketo Kato, Shota Nakamura, Tetsuya Mizuno, Toyofumi Fengshi Chen-Yoshikawa","doi":"10.1007/s10147-026-03164-2","DOIUrl":"10.1007/s10147-026-03164-2","url":null,"abstract":"<p><strong>Background: </strong>Selecting the optimal surgical strategy for lung cancer patients with interstitial lung disease (ILD) remains difficult. This study evaluated the prognostic value of a newly proposed surgical indicator-the predicted ILD Gender-Age-Physiology (GAP) stage-which incorporates predicted postoperative pulmonary function into the conventional ILD-GAP stage.</p><p><strong>Methods: </strong>This study retrospectively analyzed 125 patients with clinical stage 1 lung cancer and ILD who underwent surgery during 2011-2023. Postoperative outcomes were compared according to surgical procedure and predicted ILD-GAP stage.</p><p><strong>Results: </strong>The 5-year overall survival (OS) rate was markedly superior in patients who underwent anatomical resection with a predicted ILD-GAP stage ≤ 2 than in those who underwent wedge resection (75.0% vs. 21.3%, p < 0.001). In contrast, survival did not differ between anatomical resection with a predicted ILD-GAP stage 3 and wedge resection (27.8% vs. 21.3%, p = 0.934). Multivariate analysis identified diffusing capacity of carbon monoxide (p = 0.043), anatomical resection with a predicted ILD-GAP stage ≤ 2 (p = 0.009), and pathological stage 1 (p = 0.035) as independent predictors of prognosis. Furthermore, the predicted ILD-GAP stage provided superior prognostic accuracy for 5-year OS compared with the original ILD-GAP stage (area under the curve: 0.735 vs. 0.653; p = 0.040).</p><p><strong>Conclusions: </strong>The proposed surgical indicator enhanced prognostic stratification in lung cancer patients with ILD. In particular, anatomical lung resection in patients with a predicted ILD-GAP stage ≤ 2 was identified as an independent favorable prognostic factor for 5-year OS, highlighting the importance of surgical planning.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2524-2534"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13615045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of predicted skeletal muscle index after curative-intent resection for non-small cell lung cancer.","authors":"Kenji Kameyama, Satoru Okada, Machiko Nishi, Tatsuo Furuya, Chiaki Nakazono, Atsuki Uchibori, Tomoki Nishimura, Rintaro Kawanishi, Masayoshi Inoue, Tsunehiro Ii","doi":"10.1007/s10147-026-03158-0","DOIUrl":"10.1007/s10147-026-03158-0","url":null,"abstract":"<p><strong>Background: </strong>Reduced physiological reserve and overall systemic state are important determinants of prognosis in non-small cell lung cancer (NSCLC). The predicted skeletal muscle index (pSMI), calculated from serum creatinine to cystatin C ratio, age, body weight, and hemoglobin, has been proposed as a laboratory-based surrogate of skeletal muscle mass; however, its prognostic value in surgically treated NSCLC remains unclear.</p><p><strong>Methods: </strong>We retrospectively analyzed 199 patients who underwent curative-intent resection for NSCLC between 2019 and 2023. Patients were classified into low and high pSMI groups using previously reported sex-specific cutoff values. Overall survival (OS) and relapse-free survival (RFS) were evaluated using Kaplan-Meier methods and multivariable Cox proportional hazards models. The prognostic performance of pSMI was compared with body mass index (BMI), prognostic nutritional index (PNI), and CT-derived SMI.</p><p><strong>Results: </strong>pSMI correlated with CT-derived SMI and BMI, and low pSMI was more frequent in patients with larger tumors and vascular invasion. Sixty-four patients (32.2%) were classified into the low pSMI group and 135 (67.8%) into the high pSMI group. Low pSMI was associated with worse OS and RFS. After adjustment for age, pathological stage, vascular invasion, and either BMI, PNI, or CT-derived SMI, low pSMI remained independently associated with worse RFS (adjusted hazard ratio 2.48-2.87, all p < 0.05). In contrast, BMI, PNI, and CT-derived SMI were not independently associated with RFS.</p><p><strong>Conclusions: </strong>Low pSMI was independently associated with worse RFS after resection for NSCLC. pSMI may capture aspects of systemic vulnerability and facilitate preoperative risk stratification in patients undergoing surgery for NSCLC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2470-2480"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stage-dependent differences of long-term outcomes between chemoradiotherapy and surgery for squamous cell carcinoma of the anal canal: a multicenter retrospective cohort study.","authors":"Norihiro Shimoike, Koya Hida, Takashi Sakamoto, Kazutaka Obama, Kazutaka Yamada, Kenichi Sugihara","doi":"10.1007/s10147-026-03128-6","DOIUrl":"10.1007/s10147-026-03128-6","url":null,"abstract":"<p><strong>Objectives: </strong>Efficacy comparisons between surgery and chemoradiotherapy (CRT) in the treatment of squamous cell carcinoma (SCC) of the anal canal have not been performed enough. Herein, we aim to reveal the long-term outcomes of CRT and surgery for SCC of the anal canal and to assess the optimal clinical stage-dependent treatment strategy.</p><p><strong>Methods: </strong>We retrospectively assessed patients with SCC who were treated via CRT or surgery between 1991 and 2015 at 47 medical institutions in Japan. The associations of the treatment strategy with the overall survival (OS) and the cumulative incidence of the first recurrence categorized as local failure, inguinal lymph node metastasis, or distant recurrence were examined.</p><p><strong>Results: </strong>The OS following CRT and surgery for clinical stages ≤ II were similar (adjusted hazard ratio [aHR] 0.89, 95% confidence intervals [CI] 0.48-1.63); however, surgery was associated with lower OS for clinical stage III (aHR 1.82, 95% CI 1.06-3.11). Local failure was more likely to occur after CRT, and inguinal node metastasis occurred more frequently after surgery.</p><p><strong>Conclusions: </strong>Optimal treatments for anal canal SCC differ by clinical stage. Despite lacking QOL and organ preservation data, surgery might be an alternative option for stage I-II disease regarding long-term survival. More rigorous comparative studies are warranted.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2234-2242"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of ascites on the prognostic performance of the palliative prognostic index in terminally ill cancer patients: a multicenter secondary analysis of the EASED study.","authors":"Shinobu Fukai, Hiroto Ishiki, Masanori Mori, Tomofumi Miura, Takashi Yamaguchi, Naosuke Yokomichi, Tatsuya Morita, Aikou Okamoto, Yasuhito Uezono","doi":"10.1007/s10147-026-03208-7","DOIUrl":"https://doi.org/10.1007/s10147-026-03208-7","url":null,"abstract":"<p><strong>Background: </strong>Ascites is common in patients with advanced cancer and is associated with systemic inflammation, malnutrition, and organ dysfunction. Although the Palliative Prognostic Index (PPI) is widely used to predict short-term survival in terminally ill cancer patients, ascites is not included in its components. We investigated whether ascites influences survival and modifies the prognostic performance of the PPI in terminally ill cancer patients.</p><p><strong>Methods: </strong>This was a secondary analysis of the multicenter prospective the East-Asian cross-cultural collaborative Study to Elucidate the Dying process (EASED) study conducted in 23 palliative care units in Japan. Patients were classified according to the presence of edema and ascites at admission into four groups: G1 (edema+/ascites+), G2 (edema+/ascites-), G3 (edema-/ascites+), and G4 (edema-/ascites-). The primary outcome was the distribution of PPI scores according to edema and ascites status. Secondary outcomes included overall survival (OS) and the predictive performance of PPI thresholds for survival prediction.</p><p><strong>Results: </strong>Among 1889 patients, the distribution of PPI scores differed across the four groups. Median OS was shortest in G1 (13 days), followed by G2 (15 days), G3 (17 days), and longest in G4 (28 days) (P < 0.001). Compared with G4, adjusted hazard ratios for mortality were 1.90 in G1, 1.50 in G2, and 1.58 in G3. For predicting 21-day mortality, PPI ≥ 6.5 showed high PPV (Positive Predictive Value) in patients with ascites (G1: 87.0%; G3: 80.0%), whereas NPV (Negative Predictive Value) was markedly reduced in G3 (47.0%), suggesting potential underestimation of short-term mortality when PPI < 6.5 in ascitic patients. For predicting 42-day survival, PPI ≤ 3.5 demonstrated limited PPV across groups, particularly in patients with ascites.</p><p><strong>Conclusions: </strong>Ascites is associated with shorter survival and modifies the clinical interpretation of the PPI. In patients with ascites, reliance on PPI alone may underestimate short-term mortality. Incorporating ascites assessment into prognostic evaluation may improve clinical decision-making in end-of-life care.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in the prognostic value of body mass index after curative nephrectomy for high-risk renal cell carcinoma: a multicenter cohort study.","authors":"Shigeki Koterazawa, Takayuki Sumiyoshi, Noboru Shibasaki, Toshinari Yamasaki, Noriyuki Ito, Takehiko Segawa, Koji Inoue, Sojun Kanamaru, Toru Yoshida, Kazutoshi Okubo, Yoshio Sugino, Toru Kanno, Norihiko Masuda, Masakatsu Ueda, Shuhei Koike, Akihiro Hoshiyama, Hiromasa Araki, Ken Maekawa, Takaaki Takuma, Takehiro Yamane, Yuki Kita, Takayuki Goto, Takashi Kobayashi, Kimihiko Masui","doi":"10.1007/s10147-026-03134-8","DOIUrl":"10.1007/s10147-026-03134-8","url":null,"abstract":"<p><strong>Background: </strong>Higher body mass index (BMI) has been associated with favorable prognosis in renal cell carcinoma (RCC), a phenomenon known as the \"obesity paradox\". However, this relationship may differ by sex. Moreover, previous studies have insufficiently accounted for laboratory-based nutritional status and mainly focused on low-risk populations. Consequently, the prognostic value of BMI in patients with high-risk localized RCC remains unclear.</p><p><strong>Methods: </strong>We conducted a retrospective multicenter study of patients with high-risk localized RCC who underwent curative surgery between 2010 and 2022. Patients were stratified by BMI (≥ 25 vs. < 25 kg/m²) and sex. Disease-free survival (DFS) and overall survival (OS) were evaluated using Kaplan-Meier analysis and Cox proportional hazards models adjusted for clinicopathological variables and laboratory-based nutritional biomarkers.</p><p><strong>Results: </strong>A total of 668 patients were included, of which 243 developed disease recurrence during follow-up. In the overall cohort, BMI ≥ 25 kg/m² was significantly associated with longer DFS and OS. A significant interaction between BMI and sex was observed (P = 0.043), indicating that the prognostic value of BMI differed between males and females. In multivariable sex-stratified analyses, higher BMI was independently associated with improved DFS in males (hazard ratio = 0.61), but not in females. This relationship remained robust after adjustment for laboratory-based nutritional biomarkers and in sensitivity analyses restricted to patients with preserved nutritional status.</p><p><strong>Conclusion: </strong>Higher BMI was independently associated with more favorable oncological outcomes in patients with high-risk localized RCC, particularly in males. BMI may therefore have sex-specific prognostic value in this population.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2312-2321"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148470363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Propensity score-matched comparison of survival outcomes between clear cell and non-clear cell renal cell carcinoma in cT1N0M0 disease.","authors":"Ryotaro Tomida, Yoshito Kusuhara, Marika Atagi, Fumiya Kadoriku, Tetsuhiro Yano, Mitsuki Nishiyama, Saki Kobayashi, Ryoei Minato, Keito Shiozaki, Kei Daizumoto, Yutaro Sasaki, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Junya Furukawa","doi":"10.1007/s10147-026-03159-z","DOIUrl":"10.1007/s10147-026-03159-z","url":null,"abstract":"<p><strong>Background: </strong>Non-clear cell renal cell carcinoma (nccRCC) is a rare and heterogeneous group of tumors, and data regarding its prognosis remain limited. This study primarily aimed to compare survival outcomes between clear cell RCC (ccRCC) and nccRCC, limited to papillary and chromophobe RCC, using propensity score matching (PSM). A secondary analysis evaluated prognostic differences among histological subtypes of nccRCC.</p><p><strong>Methods: </strong>We retrospectively reviewed patients who underwent curative surgery for non-metastatic RCC between 2001 and 2023. Patients with cT1N0M0 ccRCC and nccRCC (papillary and chromophobe RCC) were matched at a 2:1 ratio using PSM. Recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were compared overall and according to surgical procedure. A secondary analysis compared survival outcomes among histological subtypes of nccRCC.</p><p><strong>Results: </strong>The matched cohort included 100 patients with ccRCC and 50 with nccRCC. Five-year RFS, CSS, and OS were comparable between the groups (94.2% vs. 95.3%, P = 0.934; 100% vs. 95.3%, P = 0.564; and 96.9% vs. 100%, P = 0.573, respectively). Similar findings were observed in both radical and partial nephrectomy subgroups. In the secondary analysis, survival outcomes varied according to histological subtype among patients with nccRCC.</p><p><strong>Conclusions: </strong>After adjustment for baseline characteristics, including surgical modality, survival outcomes were comparable between cT1N0M0 ccRCC and papillary or chromophobe RCC. Surgical modality did not appear to modify these outcomes. Prognosis differed according to histological subtype among patients with nccRCC, supporting individualized treatment strategies and follow-up protocols.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2502-2511"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; sevabertinib for lung cancer, gemcitabine intravesical system and durvalumab for bladder cancer, azacitidine for leukemia, cemiplimab for skin cancer, and ropeginterferon alfa-2b for essential thrombocythemia.","authors":"Noriomi Matsumura","doi":"10.1007/s10147-026-03190-0","DOIUrl":"10.1007/s10147-026-03190-0","url":null,"abstract":"","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"2073-2074"},"PeriodicalIF":3.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}